Qualigen
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2042 Corte Del Nogal Ste B, Carlsbad, Ca...Phone Number
(760) 918-9165Website
www.qualigeninc.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Qualigen
Qualigen, Inc. (www.qualigeninc.com) is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, using similar core nanoparticle coating technology from its FDA-approved FastPack® System, which has been used successfully in diagnostics for over 15 years. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target a variety of cancer types with potentially minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. Building off its core FastPack® technology, STARS is a DNA/RNA-based treatment device for removal from circulating blood of targeted tumor-produced and viral compounds. Its facility in Carlsbad, California, is FDA and ISO Certified and its FastPRead more
Popular SearchesQualigen IncQualigen Therapeutics IncQualigenQualigen TherapeuticsQualiGeneSIC Code 28,283NAICS Code 32,325Show moreQualigen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Qualigen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Qualigen launches new products
Check if Qualigen has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Qualigen recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Qualigen
Funding: Get notified immidiatlly once Qualigen has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Qualigen had a recent Job posting/layoffs
Check out if Qualigen is spiking on competitors!
Qualigen, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Qualigen
Find 3 more new buyers
Compare Similar Companies to Qualigen
Compare insights from companies similar to Qualigen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Qualigen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Qualigen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Qualigen.
Qualigen financials insights
Gather financial insights about Qualigen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Qualigen Tech Stack
A closer look at the technologies used by Qualigen
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Promotion
Executive Move
Lateral Move
Executive Move
Promotion
Executive Move
Qualigen News & Media
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today provides a corporate update for the third quarter ending September 30, 2023 and to date:Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumoPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer ModelsQualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Qualigen
Sign Up For FreeTo access detailed company insights
Qualigen, Inc. (www.qualigeninc.com) is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, using similar core nanoparticle coating technology from its FDA-approved FastPack® System, which has been used successfully in diagnostics for over 15 years. The Company's cancer therapeutics... Read More
